Adagene_RGB.jpg
Adagene Presents Clinical Data from NEObody™ Program, ADG106, Anti-CD137 Agonist, in an Abstract at ASCO 2021 Annual Meeting
19 mai 2021 17h05 HE | Adagene Inc.
-Identified a predictive biomarker and two pharmacodynamic biomarkers that correlate with clinical efficacy and target engagement -ADG106, a fully human, ligand-blocking, agonistic anti-CD137...
Adagene_RGB.jpg
Adagene Presents Preclinical Data from Lead SAFEbody™ Program, ADG126, at the American Association for Cancer Research (AACR) Annual Meeting 2021
13 avr. 2021 07h45 HE | Adagene Inc.
SAN FRANCISCO and SUZHOU, China, April 13, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the...
Adagene_RGB.jpg
天演药业在2021年AACR年会上公布其第一个安全抗体项目ADG126的临床前数据
13 avr. 2021 07h45 HE | Adagene Inc.
中国苏州和美国旧金山, April 13, 2021 (GLOBE NEWSWIRE) -- 天演药业(以下简称“公司”或“天演”)(纳斯达克股票代码:ADAG)是一家平台驱动的临床阶段生物制药公司,致力于发现并开发以原创抗体为基石的新型癌症免疫疗法。公司今日宣布在今年的美国癌症研究协会(AACR)年会上公布其第一个安全抗体(SAFEbody™)项目ADG126的临床前数据。 ...
Adagene_RGB.jpg
天演药业公布2020年全年财务业绩及最新业务进展
01 avr. 2021 18h45 HE | Adagene Inc.
- 成功完成首次公开募股,总集资额约1.61亿美元 -- 公布了抗CD137和两个抗CTLA-4产品的临床数据 -- 将五个早期发现项目推进至新药申请的临床前研究阶段 -- 与学术界及行业内的多个合作伙伴建立了商业合作关系 -- 进一步强化了管理团队 - 中国苏州和美国旧金山, April 02, 2021 (GLOBE NEWSWIRE) --...
Adagene_RGB.jpg
Adagene Reports Full Year 2020 Financial Results and Provides Corporate Updates
31 mars 2021 07h45 HE | Adagene Inc.
- Successfully completed Initial Public Offering raising approximately US$161 million in gross proceeds--Reported clinical data for anti-CD137 and two anti-CTLA-4 programs--Advanced five discovery...
Adagene_RGB.jpg
天演药业公布ADG116临床进展
29 mars 2021 07h51 HE | Adagene Inc.
-新表位抗体(NEObody™) 候选药物ADG 116在当前I期临床试验中显示出良好的耐受性-- ADG 116药理机制的早期临床验证支持其全球临床试验扩展- 中国苏州和美国旧金山, March 29, 2021 (GLOBE NEWSWIRE) --...
Adagene_RGB.jpg
Adagene Announces Clinical Advancement for ADG116
29 mars 2021 07h45 HE | Adagene Inc.
-NEObody™ product candidate ADG116 has been well tolerated in ongoing Phase 1 clinical trial- -Promising pharmacodynamic biomarker signals demonstrate clinical proof of mechanism--Poised for global...
Adagene_RGB.jpg
天演药业宣布其第一个安全抗体ADG126完成全球I期临床试验的首批患者给药
16 mars 2021 08h05 HE | Adagene Inc.
美国旧金山和中国苏州, March 16, 2021 (GLOBE NEWSWIRE) --...
Adagene_RGB.jpg
Adagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody™ Program
16 mars 2021 08h05 HE | Adagene Inc.
SAN FRANCISCO and SUZHOU, China, March 16, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the...
Adagene_RGB.jpg
天演藥業宣佈完成首次公開招股並行使承銷商的超額配股權
12 févr. 2021 10h38 HE | Adagene Inc.
加州三藩市, Feb. 12, 2021 (GLOBE NEWSWIRE) -- 天演藥業 (Adagene Inc.)(以下簡稱「天演藥業」或「公司」)(納斯達克股票代碼:ADAG),是一家平台驅動、致力創新抗體技術癌症免疫療法發現和開發的臨床階段生物製藥企業,今天宣佈完成 8,457,100 美國存託股票(「ADS」)的首次公開發行(「IPO」),其中包括行使承銷商的超額配股權的...